Popular on PrZen
- Paras Biopharmaceuticals Finland Oy Announces Successful Development of Biologically Active Romiplostim (N-Plate® Biosimilar) Production Technology 182
- Corfu-Villa Announce New Luxury Offerings For Visitors To Corfu & Kassiopi 178
- Natural Gas Power Plant Asset Liquidation
- Halagard builds a Marketplace for Opportunity Zones to help millions of Americans
- Sparx IT Solutions in Association with Dribbble Hosted a Design Meetup
- Market Research Industry Veteran, Tom Markert, Named COO of Persky
- Somerset Trust Holding Company, Somerset Trust Company and First Bank of Lilly Announce Agreement to Merge
- Ocean Exchange Announces 2019 Partnership and Event in Fort Lauderdale
- Retired NFL Player Reflects On A Chance Encounter With Legendary Coach Eddie Robinson of Grambling State University
- Nicole Vanessa Ortiz in Becoming Her, a musical salute to chart-topping divas
Similar on PrZen
- Stemology® Releases Product with Advanced Stem Cell Technology Complex
- IAWP Wellness Coach Certification Approved By UK Health Coaches Association
- Courtney Capone joins expanding Lantek USA Business Development Team
- Productiv Doubles Capacity in Richmond to Support Growth
- CentralAir.com Working with Local Real Estate Agencies to Help Replace AC Units on Home Purchases
- Securitize Partners with C Block Capital to Bridge Traditional and Digital Capital Markets in China
Kaydence Pharma: Successful completion of Pre-IND meeting with FDA
PrZen/33284192
OSLO, Norway - Jan. 17, 2019 - PrZen -- Kaydence Pharma AS, a development stage pharmaceutical company, is pleased to report that it has successfully completed a pre-IND (Investigational New Drug) meeting with the US Food and Drug Administration (FDA). At the meeting, the FDA addressed questions regarding key components of the planned IND application and the clinical/regulatory pathway for MQ7, Kaydence Pharma's novel drug candidate for the treatment of arterial stiffness in stable renal transplant recipients with subclinical vitamin K deficiency.
"As a result of this informative meeting, we reached agreement with the FDA on the non-clinical requirements for the IND for MQ7 supporting the planned first-in-human (FIH) study. We also achieved alignment on key components of the design for the FIH study, including the ability to conduct the study in the target patient population. In addition, the FDA provided input and guidance on our clinical and regulatory development pathway. Importantly, the FDA has agreed to meet with us following completion of the FIH study to continue discussions regarding the Phase 2 and Phase 3 development programs" said Dan Rosenbaum, CEO of Kaydence.
Currently, there are no FDA approved treatments for arterial stiffness, a condition that is highly prevalent in patients with chronic kidney disease/renal transplant. Arterial stiffness is associated with decreased renal allograft function and increased risk for cardiovascular morbidity and mortality in renal transplant recipients.
About MQ7
MQ7, a pharmaceutical formulation of the vitamin K2 subtype menaquinone 7, enables the activation of a potent, local inhibitor of vascular calcification, matrix Gla protein (MGP), thereby inhibiting arterial stiffness. A substantial proportion of patients with chronic kidney disease, including those with renal transplant, do not have sufficient levels of vitamin K (subclinical vitamin K insufficiency) to allow the activation of MGP such that vascular calcification can be inhibited. In general, inactive MGP is associated with reduced kidney function and increased risk for cardiovascular morbidity and mortality. Further, subclinical vitamin K insufficiency has been associated with reduced allograft function, graft failure, and all-cause mortality in renal transplant recipients.
About Kaydence Pharma AS
Kaydence Pharma AS is a pharmaceutical company focused on development of MQ-7 for conditions associated with arterial stiffness in patients with subclinical vitamin K deficiency.
For additional information, please contact:
Daniel Rosenbaum, CEO
Email: daniel.rosenbaum@kaydencepharma.com
Or you may send inquiries to our general mailbox at: info@kaydencepharma.com
For more information see https://kaydencepharma.com/
"As a result of this informative meeting, we reached agreement with the FDA on the non-clinical requirements for the IND for MQ7 supporting the planned first-in-human (FIH) study. We also achieved alignment on key components of the design for the FIH study, including the ability to conduct the study in the target patient population. In addition, the FDA provided input and guidance on our clinical and regulatory development pathway. Importantly, the FDA has agreed to meet with us following completion of the FIH study to continue discussions regarding the Phase 2 and Phase 3 development programs" said Dan Rosenbaum, CEO of Kaydence.
Currently, there are no FDA approved treatments for arterial stiffness, a condition that is highly prevalent in patients with chronic kidney disease/renal transplant. Arterial stiffness is associated with decreased renal allograft function and increased risk for cardiovascular morbidity and mortality in renal transplant recipients.
About MQ7
MQ7, a pharmaceutical formulation of the vitamin K2 subtype menaquinone 7, enables the activation of a potent, local inhibitor of vascular calcification, matrix Gla protein (MGP), thereby inhibiting arterial stiffness. A substantial proportion of patients with chronic kidney disease, including those with renal transplant, do not have sufficient levels of vitamin K (subclinical vitamin K insufficiency) to allow the activation of MGP such that vascular calcification can be inhibited. In general, inactive MGP is associated with reduced kidney function and increased risk for cardiovascular morbidity and mortality. Further, subclinical vitamin K insufficiency has been associated with reduced allograft function, graft failure, and all-cause mortality in renal transplant recipients.
About Kaydence Pharma AS
Kaydence Pharma AS is a pharmaceutical company focused on development of MQ-7 for conditions associated with arterial stiffness in patients with subclinical vitamin K deficiency.
For additional information, please contact:
Daniel Rosenbaum, CEO
Email: daniel.rosenbaum@kaydencepharma.com
Or you may send inquiries to our general mailbox at: info@kaydencepharma.com
For more information see https://kaydencepharma.com/
Source: Kaydence Pharma
0 Comments
Latest on PrZen
- IDI Consulting Announces Office Expansion in Pittsburgh, Pennsylvania
- LoBue & Majdalany Achieves Association Management Company (AMC) Institute Accreditation for 15th year
- Lynese Lawson, D.O., Medical Director of Proactive Wellness Centers, achieves IFM Certification for the Bredesen Reversing Cognitive Decline Program
- Samantha Chez-Magbanua : Tips for managing the home responsibility of a housewife
- MC Companies Receives Multiple Nominations At 2019 Arizona Multi-housing Association Tribute Awards
- Lesley Brice, President and Partner of MC Residential LLC., Named As 2019 Chair of Autism Speaks Walk Arizona In Association with S.A.R.R.C
- Hear Directly From Leading Technology Companies on Latest Global Development in Encryption and Cloud Computing
- Stemology® Releases Product with Advanced Stem Cell Technology Complex
- Bishop Rehabilitation and Nursing Center Promotes February as Heart Disease Awareness Month
- IDI Consulting Announces Office Expansion in Pittsburgh, Pennsylvania
- IAWP Wellness Coach Certification Approved By UK Health Coaches Association
- Courtney Capone joins expanding Lantek USA Business Development Team
- Network Security Experts Launch New FREE Porn Blocker
- Productiv Doubles Capacity in Richmond to Support Growth
- New DC Energy Analyzer Charges Up on Kickstarter
- CentralAir.com Working with Local Real Estate Agencies to Help Replace AC Units on Home Purchases
- Securitize Partners with C Block Capital to Bridge Traditional and Digital Capital Markets in China
- OFFICIAL NOMINEES for the 6th Annual Reality TV Awards Announced!
- Azaleas, Wisteria and Roses: Japan's Other Spring Flowers
- XOV opens its doors to Asia and partners with ABCC Exchange